The Stem Cell Blog – Page 1730

CAR T Cells: Keeping Pace With Adverse Effects of an Emerging Therapy – Oncology Nurse Advisor

2017-05-14 Michael Zand NEWS

Cell-free synbio: a technology whose time has come – PLoS Blogs (blog)

PLoS Blogs (blog)Cell-free synbio: a technology whose time has comePLoS Blogs (blog)There is a growing sense that the use of cell-free systems is an idea whose time has come; 2017 has seen the 1st European Congress on Cell Free Synthetic Biology, call … Continue reading

2017-05-13 Michael Zand NEWS

Researchers design process to better understand how advanced melanoma adapts to immunotherapy – Science Daily

Oncology Nurse Advisor

CAR T Cells: Keeping Pace With Adverse Effects of an Emerging Therapy
Oncology Nurse Advisor
DENVER,CO — The oncology nurses’ role in monitoring and early recognition of the signs and symptoms of chimeric antigen receptor T cell (CAR T-cell) toxicities is significant considering the potential severity of these adverse effects, according to a …

2017-05-13 Michael Zand NEWS

Editas Medicine Demonstrates First Achievement of In Vivo Editing in Non-human Primate Retinas – GuruFocus.com

Editas Medicine Demonstrates First Achievement of In Vivo Editing in Non-human Primate RetinasGuruFocus.comCAMBRIDGE, Mass., May 13, 2017 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results… Continue reading

2017-05-13 Michael Zand NEWS

Editas Medicine Demonstrates First Achievement of In Vivo Editing … – GlobeNewswire (press release)

Editas Medicine Demonstrates First Achievement of In Vivo Editing …GlobeNewswire (press release)Editing rate reported at ASGCT has potential to translate into a transformative therapy for LCA10 patients.and more &raquo… Continue reading

2017-05-13 Michael Zand NEWS

Editas Medicine Demonstrates First Achievement of In Vivo Editing … – Nasdaq

Editas Medicine Demonstrates First Achievement of In Vivo Editing …NasdaqCAMBRIDGE, Mass., May 13, 2017– Editas Medicine, Inc., a leading genome editing company, today announced results from a pre-clinical study.and more &raquo… Continue reading

2017-05-13 Michael Zand NEWS

Editas Medicine Demonstrates First Achievement of In Vivo Editing in Non-human Primate Retinas – GlobeNewswire (press release)

Editas Medicine Demonstrates First Achievement of In Vivo Editing in Non-human Primate RetinasGlobeNewswire (press release)CAMBRIDGE, Mass., May 13, 2017 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today a… Continue reading

2017-05-13 Michael Zand NEWS

Editas Medicine Demonstrates First Achievement of In Vivo Editing … – GlobeNewswire (press release)

2017-05-13 Michael Zand NEWS

1
…
1,728
1,729
1,730
1,731
1,732
…
2,487

Researchers design process to better understand how advanced melanoma adapts to immunotherapy
Science Daily
The findings lay the groundwork for developing new and improved combination therapies for patients who are resistant to stand-alone immunotherapy treatments. Pembrolizumab (marketed as Keytruda) works by signaling the patient’s immune system to …

Login

Cart

Tag Archives: The Stem Cell Blog

CAR T Cells: Keeping Pace With Adverse Effects of an Emerging Therapy – Oncology Nurse Advisor

Cell-free synbio: a technology whose time has come – PLoS Blogs (blog)

Researchers design process to better understand how advanced melanoma adapts to immunotherapy – Science Daily

Editas Medicine Demonstrates First Achievement of In Vivo Editing in Non-human Primate Retinas – GuruFocus.com

Editas Medicine Demonstrates First Achievement of In Vivo Editing … – GlobeNewswire (press release)

Editas Medicine Demonstrates First Achievement of In Vivo Editing … – Nasdaq

Editas Medicine Demonstrates First Achievement of In Vivo Editing in Non-human Primate Retinas – GlobeNewswire (press release)

Editas Medicine Demonstrates First Achievement of In Vivo Editing … – GlobeNewswire (press release)